JPWO2019175224A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175224A5 JPWO2019175224A5 JP2020547371A JP2020547371A JPWO2019175224A5 JP WO2019175224 A5 JPWO2019175224 A5 JP WO2019175224A5 JP 2020547371 A JP2020547371 A JP 2020547371A JP 2020547371 A JP2020547371 A JP 2020547371A JP WO2019175224 A5 JPWO2019175224 A5 JP WO2019175224A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 230000009824 affinity maturation Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Claims (32)
- a)配列番号1に対して少なくとも95%の配列同一性を有するアミノ酸配列を含む可変重鎖領域、及び
b)配列番号3に対して少なくとも95%の配列同一性を有するアミノ酸配列を含む可変軽鎖領域、
を含む、抗CD25抗体又はその抗原結合フラグメント。 - 配列番号1のアミノ酸配列を含むか、又は配列番号2のアミノ酸配列を含む、可変重鎖領域、並びに/或いは
配列番号3のアミノ酸配列を含むか、又は配列番号4のアミノ酸配列を含む、可変軽鎖領域、
を含む、請求項1に記載の抗体又はその抗原結合フラグメント。 - a. 配列番号1のアミノ酸配列を含む可変重鎖領域及び配列番号3のアミノ酸配列を含む可変軽鎖領域、
b. 配列番号1のアミノ酸配列を含む可変重鎖領域及び配列番号4のアミノ酸配列を含む可変軽鎖領域、
c. 配列番号2のアミノ酸配列を含む可変重鎖領域及び配列番号3のアミノ酸配列を含む可変軽鎖領域、又は、
d. 配列番号2のアミノ酸配列を含む可変重鎖領域及び配列番号4のアミノ酸配列を含む可変軽鎖領域、
を含む、請求項1又は2に記載の抗体又はその抗原結合フラグメント。 - モノクローナル抗体、ドメイン抗体、Fabフラグメント、F(ab’)2フラグメント、一本鎖可変フラグメント(scFv)、scFv-Fcフラグメント、一本鎖抗体(scAb)又は単一ドメイン抗体である、請求項1~3のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- ヒト化又は完全ヒト抗原結合抗体である、請求項1~4のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- 前記抗体がIgG1、IgG2、IgG3及びIgG4アイソタイプ抗体からなる群から選択される、請求項1~5のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- 二重特異性抗体、多重特異性抗体、又は治療剤若しくは診断剤を更に含む免疫複合体に含まれる、請求項1~6のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- CD25へのインターロイキン-2(IL-2)の結合を阻害しない、請求項1~7のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- CD25を介したインターロイキン-2(IL-2)のシグナル伝達を阻害しない、請求項1~8のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- 脱フコシル化された、請求項1~9のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- ヒトCD25のエピトープに特異的に結合し、該エピトープが配列番号5のアミノ酸150~163(YQCVQGYRALHRGP)又はアミノ酸166~180(SVCKMTHGKTRWTQP)に含まれる1つ以上のアミノ酸残基を含む、請求項1~10のいずれか一項に記載の抗体又はその抗原結合フラグメント。
- 前記エピトープが配列番号5のアミノ酸150~163(YQCVQGYRALHRGP)及び配列番号5のアミノ酸166~180(SVCKMTHGKTRWTQP)を含む、請求項11に記載の抗体又は抗原結合フラグメント。
- 請求項1~12のいずれか一項に記載の抗体又はその抗原結合フラグメントの親和性成熟変異体。
- 請求項1~13のいずれか一項に記載の抗体又はその抗原結合フラグメントをコードする核酸分子。
- 請求項14に記載の核酸分子を含む核酸ベクター。
- 請求項15に記載の核酸ベクターを含む宿主細胞。
- 請求項1~13のいずれか一項に記載の抗体又はその抗原結合フラグメントを作製する方法であって、請求項16に記載の宿主細胞を培養することを含む、方法。
- 請求項1~13のいずれか一項に記載の抗体又はその抗原結合フラグメントを含む組成物。
- 薬学的に許容可能な担体又は賦形剤を更に含む、請求項18に記載の組成物。
- 癌の治療に使用される、請求項18又は請求項19に記載の組成物。
- 第2の作用物質が同時に又は任意の順序で順次に投与されることを更なる特徴とする、請求項20に記載の組成物。
- 前記第2の作用物質が免疫チェックポイント阻害剤又は癌ワクチンである、請求項21に記載の組成物。
- 前記第2の作用物質が免疫チェックポイント阻害剤であり、該免疫チェックポイント阻害剤がPD-1アンタゴニストである、請求項22に記載の組成物。
- 前記PD-1アンタゴニストが抗PD-1抗体又は抗PD-L1抗体である、請求項23に記載の組成物。
- 前記癌が固形腫瘍を含む、請求項20~24のいずれか一項に記載の組成物。
- 前記癌が血液癌を含む、請求項20~24のいずれか一項に記載の組成物。
- 腫瘍中の制御性T細胞を枯渇させるための請求項18又は請求項19に記載の組成物。
- 前記腫瘍が固形腫瘍である、請求項27に記載の組成物。
- 前記腫瘍が血液癌腫瘍である、請求項27に記載の組成物。
- 容器内に請求項18又は請求項19に記載の組成物を含むキット。
- 抗CD25抗体を作製する方法であって、請求項1~13のいずれか一項に記載の抗体を準備することと、該抗体を親和性成熟に供することとを含み、作製される抗CD25抗体がCD25に対して親抗体よりも大きな親和性を有する、方法。
- 医薬組成物を作製する方法であって、請求項31に記載の方法に従って作製された抗体を準備することと、該抗体と少なくとも1つ以上の薬学的に許容可能な賦形剤とを共配合することとを含む、方法。
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862642232P | 2018-03-13 | 2018-03-13 | |
US201862642218P | 2018-03-13 | 2018-03-13 | |
US201862642243P | 2018-03-13 | 2018-03-13 | |
US201862642248P | 2018-03-13 | 2018-03-13 | |
US201862642230P | 2018-03-13 | 2018-03-13 | |
US62/642,230 | 2018-03-13 | ||
GBGB1804027.9A GB201804027D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
US62/642,232 | 2018-03-13 | ||
US62/642,248 | 2018-03-13 | ||
GBGB1804029.5A GB201804029D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
EPPCT/EP2018/056312 | 2018-03-13 | ||
GBGB1804028.7A GB201804028D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
US62/642,218 | 2018-03-13 | ||
US62/642,243 | 2018-03-13 | ||
PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
GB1804027.9 | 2018-03-13 | ||
GB1804028.7 | 2018-03-13 | ||
GB1804029.5 | 2018-03-13 | ||
PCT/EP2019/056258 WO2019175224A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cd25 for tumour specific cell depletion |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021516976A JP2021516976A (ja) | 2021-07-15 |
JPWO2019175224A5 true JPWO2019175224A5 (ja) | 2022-03-18 |
JP7474701B2 JP7474701B2 (ja) | 2024-04-25 |
Family
ID=67903878
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗cd25抗体剤 |
JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547332A Pending JP2021516974A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547326A Pending JP2021516973A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25抗体 |
JP2020547333A Pending JP2021515566A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547331A Pending JP2021515565A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗cd25抗体剤 |
JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547332A Pending JP2021516974A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547326A Pending JP2021516973A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020547333A Pending JP2021515566A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547331A Pending JP2021515565A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗cd25 |
Country Status (14)
Country | Link |
---|---|
US (11) | US11919960B2 (ja) |
EP (8) | EP3765502A1 (ja) |
JP (8) | JP7451414B2 (ja) |
KR (3) | KR20200131861A (ja) |
CN (8) | CN112041345A (ja) |
AU (3) | AU2019233576A1 (ja) |
BR (3) | BR112020016501A2 (ja) |
CA (3) | CA3088659A1 (ja) |
CR (3) | CR20200465A (ja) |
MA (1) | MA51993A (ja) |
PE (3) | PE20210289A1 (ja) |
SG (3) | SG11202008699WA (ja) |
TW (3) | TW202003034A (ja) |
WO (8) | WO2019175216A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
CN108795858A (zh) * | 2017-04-28 | 2018-11-13 | 深圳宾德生物技术有限公司 | 高抗癌活性t细胞的筛选方法和应用 |
EP3765502A1 (en) | 2018-03-13 | 2021-01-20 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
WO2020234399A1 (en) * | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
US20230174670A1 (en) | 2020-05-14 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
WO2022106663A1 (en) * | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
CN116917318A (zh) * | 2020-11-20 | 2023-10-20 | 法国国家健康和医学研究院 | 抗cd25抗体 |
EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022182483A1 (en) | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
KR20230154012A (ko) | 2021-03-01 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 신규 바이오마커 및 이의 용도 |
CN115724971A (zh) | 2021-08-09 | 2023-03-03 | 南京诺艾新生物技术有限公司 | 重组抗人cd25抗体及其应用 |
WO2023031403A1 (en) | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
AU2022337286A1 (en) * | 2021-09-03 | 2024-02-29 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
CN115197321B (zh) * | 2022-06-02 | 2023-08-18 | 四川大学 | 靶向cd25的抗体及其用途 |
CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
CN101124244B (zh) | 2002-11-15 | 2012-10-10 | 根马布股份公司 | 抗cd25的人单克隆抗体 |
WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
JP2006517970A (ja) | 2003-02-14 | 2006-08-03 | ユニバーシティ オブ サザン カリフォルニア | 癌免疫療法のための組成物及び方法 |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
WO2008003473A2 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
CA2661023C (en) | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
JP5746183B2 (ja) * | 2009-09-22 | 2015-07-08 | プロビオゲン アーゲー | 特定のグリカン構造を含有する分子を生成する方法 |
WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
EP2378287A1 (en) * | 2010-04-15 | 2011-10-19 | TXCell | New method for isolating Tr1 cells |
RU2598711C2 (ru) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
DK2970486T3 (en) * | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
AU2014233503A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
US20150010539A1 (en) * | 2013-03-15 | 2015-01-08 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
SG11201509982UA (ja) * | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CR20170014A (es) | 2014-07-16 | 2017-10-17 | Hoffmann La Roche | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer |
NZ728688A (en) * | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
CA2957387A1 (en) | 2014-08-07 | 2016-02-11 | Hyogo College Of Medicine | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody |
US11147652B2 (en) | 2014-11-13 | 2021-10-19 | Align Technology, Inc. | Method for tracking, predicting, and proactively correcting malocclusion and related issues |
HRP20221083T1 (hr) * | 2014-11-20 | 2022-11-25 | F. Hoffmann - La Roche Ag | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1 |
EA202090956A3 (ru) * | 2014-11-21 | 2020-12-30 | Бристол-Майерс Сквибб Компани | Антитела к cd73 и их применения |
AU2015369683B2 (en) * | 2014-12-23 | 2020-12-10 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
WO2016150899A2 (en) * | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
NZ741404A (en) * | 2015-10-23 | 2024-03-22 | Univ California | Anti-il-2 antibodies and compositions and uses thereof |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
KR102068600B1 (ko) * | 2016-03-04 | 2020-01-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Pdl-1 항체, 그 약학적 조성물 및 그 용도 |
CA3016187A1 (en) * | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
AU2017278193B9 (en) * | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
JP6831651B2 (ja) | 2016-07-04 | 2021-02-17 | 川崎重工業株式会社 | ワークの袋詰め装置 |
EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
US11119165B2 (en) | 2017-06-28 | 2021-09-14 | North Carolina State University Office of Research Commercialization | Photonic band-gap resonator for magnetic resonance applications |
JP7225135B2 (ja) | 2017-07-06 | 2023-02-20 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のための化合物及び方法 |
EP3765502A1 (en) | 2018-03-13 | 2021-01-20 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
RU2020128081A (ru) | 2018-03-13 | 2022-04-13 | Таск Терапьютикс Лтд | Антитело против cd25 для опухоль-специфической клеточной деплеции |
KR20200003558A (ko) | 2018-07-02 | 2020-01-10 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치 |
KR102080909B1 (ko) | 2018-07-06 | 2020-02-24 | 한국수력원자력 주식회사 | 원자로의 해체 시스템 |
-
2019
- 2019-03-13 EP EP19709954.2A patent/EP3765502A1/en active Pending
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 KR KR1020207029221A patent/KR20200131861A/ko not_active Application Discontinuation
- 2019-03-13 EP EP19711315.2A patent/EP3765511A1/en active Pending
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 CN CN201980019235.6A patent/CN112041345A/zh active Pending
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/en active Application Filing
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/en unknown
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 JP JP2020547332A patent/JP2021516974A/ja active Pending
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/en active Active
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/en active Application Filing
- 2019-03-13 CN CN201980019234.1A patent/CN112074536A/zh active Pending
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 CN CN201980019241.1A patent/CN112020512A/zh active Pending
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/en active Active
- 2019-03-13 JP JP2020547326A patent/JP2021516973A/ja active Pending
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 CN CN201980019248.3A patent/CN112020514A/zh active Pending
- 2019-03-13 EP EP19709956.7A patent/EP3765504A1/en active Pending
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko unknown
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/en unknown
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
- 2019-03-13 JP JP2020547333A patent/JP2021515566A/ja active Pending
- 2019-03-13 CN CN201980019257.2A patent/CN112218891A/zh active Pending
- 2019-03-13 CA CA3088659A patent/CA3088659A1/en not_active Abandoned
- 2019-03-13 CA CA3088671A patent/CA3088671A1/en active Pending
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/en active Application Filing
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 AU AU2019233581A patent/AU2019233581A1/en active Pending
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 CN CN201980019256.8A patent/CN112020516A/zh active Pending
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko unknown
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 JP JP2020547331A patent/JP2021515565A/ja active Pending
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/en active Pending
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/en unknown
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/en unknown
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/en active Active
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/en unknown
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/en active Active
- 2019-03-13 CN CN201980019247.9A patent/CN112020513A/zh active Pending
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 CA CA3088246A patent/CA3088246A1/en not_active Abandoned
- 2019-03-13 CN CN201980019249.8A patent/CN112020515A/zh active Pending
-
2020
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019175224A5 (ja) | ||
JP6908722B2 (ja) | 抗pd−1抗体及びその使用 | |
JP6518005B2 (ja) | Pd−l1抗体 | |
US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
JP6866294B2 (ja) | 抗pd−l1抗体 | |
JP7254699B2 (ja) | 抗bcma重鎖のみ抗体 | |
JPWO2019175223A5 (ja) | ||
JPWO2019175226A5 (ja) | ||
JP6719477B2 (ja) | 抗tim−3抗体 | |
US11518815B2 (en) | Anti-ROR1 antibodies and methods of making and using thereof | |
JPWO2019175215A5 (ja) | ||
JP6709215B2 (ja) | 抗tim−3抗体 | |
JPWO2019175220A5 (ja) | ||
JPWO2019175217A5 (ja) | ||
JPWO2019175216A5 (ja) | ||
JPWO2019175222A5 (ja) | ||
JP2020515247A5 (ja) | ||
JP2019517773A (ja) | 抗lag−3抗体 | |
JP2018531219A6 (ja) | Pd−l1抗体 | |
US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
JP2020522280A5 (ja) | ||
JP2020522281A5 (ja) | ||
JP2020533965A5 (ja) | ||
JP2020531003A5 (ja) | ||
RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции |